• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura touts data for Memspatch insulin micro-needle device

May 18, 2017 By Sarah Faulkner

Nemaura PharmaNemaura Pharma‘s Memspatch insulin micro-needle device compared well against a pen injector in an 18-patient clinical trials, according to the company.

The group of Type I diabetic patients were given insulin using either the Memspatch device or a traditional pen injector. Researchers evaluated the patient’s pain levels using a number pain rating score from 0 to 10. Patients were also asked to record their experiences with the devices and to reflect on the pain immediately following administration.

Pain intensity and sharpness reached 5 for several patients using the pen injector. Patients who used the Memspatch device reported a 0 or 1 when it was applied to the arm or thigh, according to Nemaura.

The Memspatch insulin delivery device administers insulin through shallow micro-needles, with skin-penetration kept to a depth of 2 millimeters to 4 millimeters. Pen injector needles often penetrate 9 millimeters into the skin.

“Needle phobia is a major barrier to health. We have looked carefully at the human factors restricting diabetics wanting to self-administer insulin, and have developed the Memspatch IMD to avoid puncture pain, and to improve treatment compliance,” CEO Faz Chowdhury said in prepared remarks. “Over 50% of adults with Type II diabetes delay starting insulin due to needle fear, and over 90% feel fear reactions every time they inject. So we would encourage the take-up of Memspatch IMD technology to help diabetics better manage their condition.”

The company is slated to evaluate its Memspatch device with other medicines later this year.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Nemaura Pharma

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS